Design, synthesis and in vitro PDE4 inhibition activity of certain quinazolinone derivatives for treatment of asthma

Medicinal Chemistry Research

Volumn 21, Issue 11, 2012, Pages 3327-3335

  Elansary, Afaf K ^a   Kadry, Hanan H ^a   Ahmed, Eman M ^a   Sonousi, Amr Sayed Motawi ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

Asthma; Phosphodiesterase 4 (PDE4) inhibitors; Quinazolinone; Synthesis

Indexed keywords

3 BUTYL 2 (3 NITROPHENYL) 2,3 DIHYDROQUINAZOLIN 4(1H) ONE; 3 BUTYL 2 (4 HYDROXY 3 METHOXYPHENYL) 2,3 DIHYDROQUINAZOLIN 4(1H) ONE; 3 BUTYL 2 [2 (3 HYDROXYBENZYLIDENE)HYDRAZINYL]QUINAZOLIN 4(3H) ONE; 3 BUTYL 2 [2 [4 (DIMETHYLAMINO)BENZYLIDENE]HYDRAZINYL]QUINAZOLIN 4(3H) ONE; 3 BUTYL 2 [4 (DIMETHYLAMINO)PHENYL] 2,3 DIHYDROQUINAZOLIN 4(1H) ONE; 4 BUTYL 1 (3 HYDROXYPHENYL)[1,2,4]TRIAZOLO[4,3 A]QUINAZOLIN 5(4H) ONE; 4 BUTYL 1 (3 NITROPHENYL)[1,2,4]TRIAZOLO[4,3 A]QUINAZOLIN 5(4H) ONE; 4 BUTYL 1 (4 HYDROXY 3 METHOXYPHENYL)[1,2,4]TRIAZOLO[4,3 A]QUINAZOLIN 5(4H) ONE; 4 BUTYL 1 [4 (DIMETHYLAMINO)PHENYL][1,2,4]TRIAZOLO[4,3 A]QUINAZOLIN 5(4H) ONE; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; PHOSPHODIESTERASE IVB; QUINAZOLINONE DERIVATIVE; ROLIPRAM; UNCLASSIFIED DRUG;

ASTHMA; CONFERENCE PAPER; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; IN VITRO STUDY; PROTON NUCLEAR MAGNETIC RESONANCE;

EID: 84871404580     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-011-9846-3     Document Type: Conference Paper

References (23)

1. Adelroth E, Rosenhall L, Johansson SA, Linden M, Venge P (1990) Inflammatory cells and eosinophilic activity in asthmatics investigated by bronchoalveolar lavage: The effects of antiasthmatic treatment with budesonide or terbutaline. Am Rev Respir Dis 142:91-99
2. Barnes PJ (1992) Frontiers in medicine: new aspects of asthma. J Intern Med 231:453-461
3. Butcher RW, Sutherland EW (1962) Adenosine 30,50-phosphate in biological materials. J Biol Chem 237:1244-1250
4. Chen J, Wu D, He F, Liu M, Wu H, Ding J, Su W (2008) Gallium(III) triflate-catalyzed one-pot selective synthesis of 2,3-dihydroquinazolin-4(1H)- ones and quinazolin-4(3H)-ones. Tetrahedron Lett 49:3814-3818
5. Clark RH, Wagner EC (1944) Isatoic anhydride. I. Reactions with primary and secondary amines and with some amides. J Org Chem 9:55-67
6. Crespo MI, Pages L, Vega A, Segarra V, Lopez M, Domenech T, Miralpeix M, Beleta J, Ryder H, Palacios JM (1998) Design, synthesis, and biological activities of new thieno[3,2-d]pyrimidines as selective type 4 phosphodiesterase inhibitors. J Med Chem 4:4021-4035
7. Crocker CI, Townley RG (1999) Therapeutic potential of phosphodiesterase 4 inhibitors in allergic diseases. Drugs Today 35:519-535
8. Djukanovic R, Roche WR, Wilson JW, Beasley CRW, Twentyman OP, Howarth PH, Holgate ST (1990) Mucosal inflammation in asthma. Am Rev Respir Dis 142:434-457
9. Elmaaty TA, Castle LW (2005) Chromate oxidation of a-nitro alcohols to a-nitro ketones: significant improvements to a classic method. Molecules 10:1458-1461
10. Fisher DA, Smith JF, Pillar JS, Denis SH, Cheng JB (1998) Isolation and characterization of PDE 8A, a novel human cAMP specific phosphodiesterase. Biochem Biophys Res Commun 246:570-577
11. Glaser T, Traber J (1984) TVX 2706 -A new phosphodiesterase inhibitor with anti-inflammatory action. Agents Actions 15: 341-348
12. Holgate ST (1988) Inflammatory cells and their mediators in the pathogenesis of asthma. Postgrad Med J 64:S82-S95
13. Juilfs DM, Soderling S, Burns F, Beavo JA (1999) Cyclic GMP as substrate and regulator of cyclic nucleotide phosphodiesterases (PDEs). Rev Physiol Biochem Pharmacol 135:67-104
14. Kottke K, Kuhmstedt H, Grafe I, Knoke D, Schleuder M (1990) Synthesis of compounds having an aminoguanidine structure. Part 17. Hydrazinolysis of 3-Alkyl-And 3-Aryl-substituted 4-oxo-2-thioxo-1,2,3,4-tetrahydroquinazolines. Pharmazie 45:30-33
15. Lanfear J, Robas NM (1999) Mammalian cyclic nucleotide phosphodiesterases and their cDNAsequences. Eur Pat Appl EP 967284 A1
16. Piaz VD, Giovannoni MP (2000) TVX 2706-A new phosphodiesterase inhibitor with anti-inflammatory action. Eur J Med Chem 35:463-480
17. Reed CE (1988) Basic mechanisms of asthma. Role of inflammation. Chest 94:175-177
18. Reques FG, Rodriguez JLE (1999) Tolerability of leukotriene modifiers in asthmas. Biodrugs 11:385-394
19. Rodriguez-Franco MI, Dorronsoro I, Castro A, Martinez A (2000) Hindered inversion/rotation in diheteroaryl alkyl amines with a N-(1-pyrazolyl) group: dynamic NMR and molecular modelling studies. Tetrahedron 56:1739-1743
20. Shafik RM, Hazzaa AAB, Habib NS (1979) 2-(Mono-And dinitrophenylthio)-3- substituted-4(3H)-quinazolinones: potential sedative-hypnotics agents. Pharmazie 34:148-150
21. Tormena CF, Freitas MP, Rittner R, Abraham RJ (2002) A 1H NMR and molecular modelling investigation of diastereotopic methylene hydrogen atoms. Magn Reson Chem 40:279-283
22. Torphy JT (1998) Phosphodiesterase isozymes molecular targets for novel antiasthma agents. Am J Respir Crit Care Med 157: 351-370
23. Vassallo R, Lipsky JJ (1998) Theophylline: recent advances in the understanding of its mode of action and uses in clinical practice. Mayo Clin Proc 73:346-354